Oryx International Growth’s results for the 12 months ended 31 March 2024 show the trust generating an NAV uplift of 12.2%. However, the share price fell by 1.8% as the discount widened from 19.0% to 29.1%. There is no dividend. The manager notes that performance was driven by takeovers or offers for significant parts of […]
In QuotedData’s morning briefing 4 July 2024: Polar Capital Global Financials (PCFT) has published six-month numbers covering the period ended 31 May 2024. The trust beat its benchmark, returning 18.2% in NAV terms and 23.3% in share price terms versus 15.9% for the MSCI All Countries World Financials Index. [We covered many of the reasons […]
Chrysalis Investments published its interim results for the six months ended 31 March 2024 on Friday. The NAV rose from 134.65p to 147.46p over the period, an increase of 9.5%, and the share price was up by 33.4%, as the discount narrowed to 43.7%. However, the discount has widened again since as more bad news […]
Alongside its results, the trust has announced plans for a 15% tender offer. JPMorgan European Discovery says that over the year to 31st March 2024 its total return on net assets was 6.8%, outperforming the benchmark (MSCI Europe (ex UK) Small Cap Index) which returned 5.9%. The total return to shareholders was 13.0%, as the […]
Cordiant Digital Infrastructure’s results to end March 2024 show an improvement in its NAV to 120.1p, contributing to an NAV return for the period of 9.3% (that would have been 11% but for adverse foreign exchange movements), and an increase in the dividend to 4.2p (up 5%), offset by a widening discount – from 28.3% […]
Syncona has added two new companies to its portfolio, iOnctura and Yellowstone Biosciences. Syncona has invested €30m (£25.7m) in iOnctura, an innovative, clinical-stage, small molecule company combating neglected and hard-to-treat cancers, and launched Yellowstone, a new oncology company pioneering soluble bispecific T-cell receptor (TCR)-based therapies, with a £16.5m commitment. iOnctura iOnctura is developing selective cancer […]
Syncona has published results for the 12 months ended 31 March 2024. The NAV edged up from 186.5p to 188.7p, giving a NAV return for the period of 1.2%, but as it turns out all of that came from the effect of buying back shares at a discount. £20.2m worth of shares were repurchased at […]
In QuotedData’s morning briefing 20 June 2024: GCP Infrastructure’s half-year numbers to end March 2024 showed a small positive NAV return of 1.2% but a much greater uplift in the share price as the discount narrowed giving shareholders a return of 12.5%. As usual, the dividend is maintained at 3.5p for the six-month period. No […]
Ashoka WhiteOak Emerging Markets (AWEM) has published its first annual report, covering the period from its incorporation on 15 March 2023 to 31 March 2024. The company listed on the Premium Segment of the Main Market of the London Stock Exchange on 3 May 2023. In its inaugural accounting period, Ashoka WhiteOak Emerging Markets generated […]
In QuotedData’s morning briefing 18 June 2024: abrdn Diversified Income & Growth (ADIG) has announced details of its planned return of £115m of capital (38p per share) via a B share scheme. The distribution needs to be approved at a meeting that will be held on 3 July 2024. The money should be with shareholders […]
Please review our cookie, privacy & data protection and terms and conditions policies and, if you accept, please select your place of residence and whether you are a private or professional investor.
Due to data protection policies, USA residents can not access our data.
Your content has been curated
